miR-26a exerts broad-spectrum antiviral effects via the enhancement of RIG-I-mediated type I interferon response by targeting USP15

  • Microbiol Spectr. 2023 Nov 29:e0312423. doi: 10.1128/spectrum.03124-23.
Jikai Zhang  1  2 ,  Chunyang Li  1  2 ,  Yao Hou  1  2 ,  Dan Liu  1  2 ,  Qiudi Li  1  2 ,  Zijie Wang  1  2 ,  Renxian Tang  1  2 ,  Kuiyang Zheng  1  2 ,  Hongbo Guo  1  2 ,  Wenshi Wang  1  2
Affiliations
  • 1. Department of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.
  • 2. Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.
PMID: 38019020 DOI: 10.1128/spectrum.03124-23
Abstract

miR-26a serves as a potent positive regulator of type I interferon (IFN) responses. By inhibiting USP15 expression, miR-26a promotes RIG-I K63-ubiquitination to enhance type I IFN responses, resulting in an active Antiviral state against viruses. Being an intricate regulatory network, the activation of type I IFN responses could in turn suppress miR-26a expression to avoid the disordered activation that might result in the so-called "type I interferonopathy." The knowledge gained would be essential for the development of novel Antiviral strategies against viral Infection.

Keywords
RIG-I; USP15; broad spectrum; innate immunity; miR-26a; ubiquitination.
Products